To inquire phenotypic plasticity of trametinib-resistant melanoma cells, changes in activities of crucial components of BRAF/MEK/ERK signaling induced during alternating periods of trametinib withdrawal and rechallenge were investigated for their reversibility (Figure 1). This evidence concerns the gene MAP2K7 and melanoma.